Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000763 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00000763 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 42 participants.
The verdict
NCT00000763, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of the drug. Since evidence shows that neovascularization is important in the development of Kaposi's sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with the disease.
Interventions
- DRUG TNP-470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Est. Completion | 1997-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000763
The ClinicalTrials.gov registry entry for NCT00000763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TNP-470 is the first listed.
NCT00000763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000763 about?
NCT00000763 is a clinical study titled "A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma". To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of the drug. Since evidence shows that neovascularization is important in the development of Kaposi's sarcoma, drugs that...
What is the current status of trial NCT00000763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. Estimated completion is 1997-02.
What interventions are being tested in trial NCT00000763?
The interventions under investigation include: TNP-470 (DRUG).
Who is sponsoring clinical trial NCT00000763?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.